Search
Sotatercept
go.drugbank.com/drugs/DB12118ApprovedInvestigational[L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH. … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.
Butylscopolamine
go.drugbank.com/drugs/DB09300ApprovedInvestigationalVet approvedIt is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. … It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring.
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar works to block bile acid synthesis.[A264234]
Libivirumab
go.drugbank.com/drugs/DB17748ExperimentalIt is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Categories: Preparations With No Effect on Uric Acid MetabolismStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. … [A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Cisapride
go.drugbank.com/drugs/DB00604ApprovedWithdrawnIn many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. … The FDA issued a warning letter regarding this risk to health care professionals and patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSimvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigationalThe clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.
Mixtures: EZETIMIBE E SIMVASTATINA DOC GENERICI, EZETIMIBE E SIMVASTATINA DOC GENERICISynonyms: 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-oneDihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedTo know more about this mixture, please visit [DB01049] … This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.[T195] Both compounds are hydrogenated ergot derivatives.
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary … [L56058] Developed to address the clinical limitations of daily therapies, the pegylated nature of navepegritide allows for once-weekly dosing while providing sustained systemic exposure to CNP, which